Eyenuk, Inc. Expands into Germany with Launch of EyeArt® Artificial Intelligence Eye Screening for Diabetic Retinopathy

CE_logo_nemko_EyeArt_resized

LOS ANGELES, California, Oct. 2, 2018 – Eyenuk, Inc. announces its expansion into Germany with the adoption of EyeArt® artificial intelligence (AI) technology for the screening of diabetic retinopathy at Diabetes Center Mergentheim in Bad Mergentheim, Germany. The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic […]

Continue Reading »

Eyenuk Inc.’s AI-based diabetic retinopathy screening software EyeArt™ tested with portable smartphone-based imaging device in new study indicating potential for highly sensitive yet cost-effective mass retinal screening

Nature Eye Article

A new study published in the international ‘Eye’ journal (Springer Nature) demonstrated very high sensitivity for detecting any diabetic retinopathy (95.8%) and sight-threatening diabetic retinopathy (99.1%) using EyeArt™ automated screening software with Remidio Fundus on Phone system. LOS ANGELES, CA, March 12, 2018 — Eyenuk, Inc., a leading developer of advanced clinically supported artificial intelligence […]

Continue Reading »

Eyenuk, Inc. Receives Health Canada Approval for EyeArt™, an AI-enabled Cloud-based Automated Diabetic Retinopathy Screening Software

MDSAP_Certified_Health_Canada_Approved_EyeArt

Eyenuk’s quality management system has been registered under the Medical Device Single Audit Program (“MDSAP”) as conforming to the requirements of ISO 13485:2003, after successfully completing an audit for the relevant quality management system requirements of the U.S. Food and Drug Administration and Health Canada. LOS ANGELES, CA, March 8, 2018 — Eyenuk, Inc., a […]

Continue Reading »

Preventing the preventable: Combating diabetic retinopathy in at-risk women

IMG_0499_PP

World Diabetes Day is the world’s largest diabetes awareness campaign. This year’s theme, Women and Diabetes, promotes the importance of access for all women with diabetes to education, treatment and care. Oslo University Hospital/University of Oslo in collaboration with Eyenuk Inc. recently highlighted the importance of early detection of diabetic retinopathy (DR) in women in […]

Continue Reading »

Deep Learning for Diabetic Eye Screening

deeplearningtopreventblindness

There is a lot of talk about the use of “deep learning” in the screening and identification of diabetic retinopathy (DR) lately. “Deep learning” is familiar to many in the tech industry, but is a relatively new concept in eye care. In very simple terms, deep learning is attempting to bring technology closer to artificial […]

Continue Reading »

EASD 2016 in Munich: EyeArt™ 2.0 validation on over 78,685 consecutive patient cases

Picture2

Eyenuk Inc. is presenting a validation study titled  “Automated diabetic retinopathy screening: large-scale study on consecutive patient visits in a primary care setting” at the 52nd EASD Annual Meeting in Munich, Germany. Details are as indicated below Venue: Meyerhof Hall, ICM Messe München, Messegelände, 81823 München, Germany Presenter: Kaushal Solanki, Ph.D Scheduled time: Wednesday, September 14, 2016, 14:30  – 14:45 Session: […]

Continue Reading »

EyeArt™ validated against 7-field ETDRS stereoscopic reference standard, an EU Retina Study

Picture1

Eyenuk Inc. is presenting a study titled  “Comprehensive Clinical Validation Study of a Fully-automated Diabetic Retinopathy Screening System using Color Fundus Images Against 7-field ETDRS Stereoscopic Reference Standard” at EU Retina 2016, in Copenhagen, Denmark. Details are as indicated below Venue: Auditorium 6, Bella Center, Copenhagen, Denmark Presenter: Kaushal Solanki, Ph.D Scheduled time: Friday, September 09, 2016, 11:42 am – […]

Continue Reading »

Eyenuk Announces CE Mark and Commercial Launch of Eyeart 2.0, The Second Generation of its Fully Automated Diabetic Retinopathy (DR) Screening Software

CE_logo_nemko_EyeArt_resized

WOODLAND HILLS, Calif. – June 29, 2016 – Eyenuk, Inc., developer of advanced retinal image analysis solutions to identify eye disease, today announced receipt of the CE Mark and the launch of the second generation of its EyeArt fully automated diabetic retinopathy (DR) screening software. The company plans to roll out EyeArt 2.0 to selected, […]

Continue Reading »